Literature DB >> 30656518

Promoter cross-talk affects the inducible expression of intronic shRNAs from the tetracycline response element.

Seong Kyun Park1, Byung Joon Hwang1, Yun Kee2.   

Abstract

BACKGROUND: RNA interference (RNAi), defined as double-stranded, RNA-mediated gene silencing, is a useful tool for functional genomic studies. Along with increasing information about genomic sequences due to the innovative development of genome-sequencing technologies, functional genomic technologies are needed to annotate the genome and determine the processes by which each gene is regulated. Lentiviral vectors have been used to efficiently deliver reagents, such as small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs), into cells and tissues for functional genomic analyses.
OBJECTIVE: We developed a lentiviral vector that efficiently expresses intronic shRNA from the tetracycline regulatory element (TRE) promoter in a doxycycline-dependent manner.
METHODS: We developed a lentiviral vector system that contains reverse tetracycline-controlled transactivator 3 (rtTA3) and the TRE promoter, which are necessary for the doxycycline-inducible expression of shRNAs that are expressed as intronic miR-30a precursors. We then measured the cross-talk between the cytomegalovirus (CMV) and TRE promoters in the vector.
RESULTS: We found that nearby promoters influence each other and that the TRE promoter should be located far from other promoters, such as the CMV promoter, in a vector. The orientation of a promoter with respect to other promoters also influences its transcriptional activity. A head-to-head orientation of the CMV and TRE promoters maintains the lowest level of transcription from TRE in the absence of doxycycline, compared to the tail-to-tail and head-to-tail orientations.
CONCLUSION: Based on these findings, we were able to construct a lentiviral vector that faithfully expresses intronic miR-30a shRNA precursors in a doxycycline-inducible manner.

Entities:  

Keywords:  Lentiviral vector; Promoter cross-talk; ShRNA; Tetracycline-inducible promoter

Mesh:

Substances:

Year:  2019        PMID: 30656518     DOI: 10.1007/s13258-019-00784-z

Source DB:  PubMed          Journal:  Genes Genomics        ISSN: 1976-9571            Impact factor:   1.839


  31 in total

1.  Inducible shRNA expression for application in a prostate cancer mouse model.

Authors:  Frank Czauderna; Ansgar Santel; Michael Hinz; Melanie Fechtner; Birgit Durieux; Gerald Fisch; Frauke Leenders; Wolfgang Arnold; Klaus Giese; Anke Klippel; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

2.  Gene knockdown by ecdysone-based inducible RNAi in stable mammalian cell lines.

Authors:  Danny Rangasamy; David J Tremethick; Ian K Greaves
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 3.  Use of HIV as a gene transfer vector.

Authors:  Krzysztof Pluta; Magdalena Marta Kacprzak
Journal:  Acta Biochim Pol       Date:  2009-11-23       Impact factor: 2.149

4.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Authors:  Stéphane Palfi; Jean Marc Gurruchaga; G Scott Ralph; Helene Lepetit; Sonia Lavisse; Philip C Buttery; Colin Watts; James Miskin; Michelle Kelleher; Sarah Deeley; Hirokazu Iwamuro; Jean Pascal Lefaucheur; Claire Thiriez; Gilles Fenelon; Cherry Lucas; Pierre Brugières; Inanna Gabriel; Kou Abhay; Xavier Drouot; Naoki Tani; Aurelie Kas; Bijan Ghaleh; Philippe Le Corvoisier; Patrice Dolphin; David P Breen; Sarah Mason; Natalie Valle Guzman; Nicholas D Mazarakis; Pippa A Radcliffe; Richard Harrop; Susan M Kingsman; Olivier Rascol; Stuart Naylor; Roger A Barker; Philippe Hantraye; Philippe Remy; Pierre Cesaro; Kyriacos A Mitrophanous
Journal:  Lancet       Date:  2014-01-10       Impact factor: 79.321

5.  RNA polymerase III transcribes human microRNAs.

Authors:  Glen M Borchert; William Lanier; Beverly L Davidson
Journal:  Nat Struct Mol Biol       Date:  2006-11-12       Impact factor: 15.369

6.  Single-vector inducible lentiviral RNAi system for oncology target validation.

Authors:  Dmitri Wiederschain; Susan Wee; Lin Chen; Alice Loo; Guizhi Yang; Alan Huang; Yan Chen; Giordano Caponigro; Yung-Mae Yao; Christoph Lengauer; William R Sellers; John D Benson
Journal:  Cell Cycle       Date:  2009-02-25       Impact factor: 4.534

7.  Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic.

Authors:  Jeffery C Giering; Dirk Grimm; Theresa A Storm; Mark A Kay
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

8.  Silencing of mammalian genes by tetracycline-inducible shRNA expression.

Authors:  Sven Kappel; Yves Matthess; Manfred Kaufmann; Klaus Strebhardt
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

9.  shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell.

Authors:  Jing Yuan; Xiaobo Wang; Ying Zhang; Xiaoxiang Hu; Xuemei Deng; Jing Fei; Ning Li
Journal:  Mol Biol Rep       Date:  2006-03       Impact factor: 2.742

10.  Intronic microRNA (miRNA).

Authors:  Shi-Lung Lin; Joseph D Miller; Shao-Yao Ying
Journal:  J Biomed Biotechnol       Date:  2006
View more
  2 in total

Review 1.  Toward Tightly Tuned Gene Expression Following Lentiviral Vector Transduction.

Authors:  Audrey Page; Floriane Fusil; François-Loïc Cosset
Journal:  Viruses       Date:  2020-12-11       Impact factor: 5.048

2.  Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency.

Authors:  Lewis E Fry; Caroline F Peddle; Marta Stevanovic; Alun R Barnard; Michelle E McClements; Robert E MacLaren
Journal:  CRISPR J       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.